Clinical Trial Detail

NCT ID NCT03965845
Title A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Calithera Biosciences, Inc
Indications

Advanced Solid Tumor

colorectal cancer

lung non-small cell carcinoma

Therapies

Palbociclib + Telaglenastat

Age Groups: adult senior

No variant requirements are available.